Company

Hinova Pharmaceuticals' HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs
Clinical trial resultsHinova Pharmaceuticals

Hinova Pharmaceuticals’ HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs

Hinova Pharmaceuticals Inc. (SHA: 688302) announced that Phase IIa clinical data for HP515 tablets, its proprietary oral THR‑β (thyroid hormone receptor beta) agonist, have been accepted as a Late‑Breaking Abstract…

Easton Pharmaceutical Wins NMPA Approval for Vitamin K1 Injection Pediatric Spec – Third Generic to Achieve Bioequivalence for Infant Hemorrhagic Disease Prevention

Easton Pharmaceutical Wins NMPA Approval for Vitamin K1 Injection Pediatric Spec – Third Generic to Achieve Bioequivalence for Infant Hemorrhagic Disease Prevention

Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies

Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CRO / CMO / CDMOCTSMED Pharmaceutical Technology

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

AbbVieClinical trial results

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
Market launchOTCMKTS: RHHBY

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
HIV / AIDS careMerck

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Show More